MMPP
MMPP is a novel VEGFR2 inhibitor with anti-inflammatory and potential anticancer activity, inhibits STAT3, inhibits angiogenesis via VEGFR2/AKT/ERK/NF-kappaB pathway, and can be used to alleviate myocardial injury.
Product Specifications
Stability
≥ 2 years
Purity
>98% (HPLC)
Weight
270.32
Molecular Formula
C17H18O3
Notes
Research use only, not for human use.
Receptor
STAT | VEGFR
CAS Number
1895957-18-2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1391549-01 0.05 mg (E-Coli)
Recombinant Encephalitozoon cuniculi Pyruvate kinase (PYK1), partial
Ask
View Details 
MBS1391549-02 0.05 mg (Baculovirus)
Recombinant Encephalitozoon cuniculi Pyruvate kinase (PYK1), partial
Ask
View Details MBS1391549-03 0.2 mg (E-Coli)
Recombinant Encephalitozoon cuniculi Pyruvate kinase (PYK1), partial
Ask
View Details 
MBS1391549-04 0.5 mg (E-Coli)
Recombinant Encephalitozoon cuniculi Pyruvate kinase (PYK1), partial
Ask
View Details MBS1391549-05 0.2 mg (Yeast)
Recombinant Encephalitozoon cuniculi Pyruvate kinase (PYK1), partial
Ask
View Details 
MBS1391549-06 0.05 mg (Mammalian-Cell)
Recombinant Encephalitozoon cuniculi Pyruvate kinase (PYK1), partial
Ask
View Details